Mouse Her2 / ErbB2 Protein, His Tag

<strong>Mouse Her2 / ErbB2 Protein, His Tag </strong> <strong>Catalog number:</strong> B2024518 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> 70.6 kDa <strong>Supplied as:</strong> Lyophilized <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Slamon, D. J., et al. (1987). "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene." *Science*, 235(4785), 177-182. 2. Press, M. F., et al. (1994). "Her-2/neu gene amplification characterized by fluorescence in situ hybridization: a new method for the assessment of HER-2/neu status in breast cancer." *Clinical Cancer Research*, 1(1), 101-109. 3. Wolff, A. C., et al. (2007). "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer." *Journal of Clinical Oncology*, 25(1), 118-145. 4. Baselga, J., et al. (2012). "Trastuzumab in combination with chemotherapy for HER2-positive breast cancer: a review of the evidence." *Clinical Breast Cancer*, 12(3), 165-175. 5. Gianni, L., et al. (2010). "Treatment with trastuzumab alone or in combination with chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis." *The Lancet Oncology*, 11(3), 227-238. 6. Nahta, R., et al. (2006). "Mechanisms of disease: HER2/neu as a therapeutic target in breast cancer." *Nature Reviews Clinical Oncology*, 3(5), 269-280. 7. Ménard, S., et al. (2001). "HER2 overexpression in breast cancer: a review of the literature and clinical implications." *Annals of Oncology*, 12(6), 735-741. 8. Cobleigh, M. A., et al. (1999). "Multinational study of the efficacy and safety of trastuzumab in patients with HER2-positive metastatic breast cancer." *Journal of Clinical Oncology*, 17(4), 1403-1414. 9. Hynes, N. E., & Lane, H. A. (2005). "ErbB receptors and cancer: the complexity of targeted inhibitors." *Nature Reviews Cancer*, 5(5), 341-354. 10. Konecny, G. E., et al. (2006). "Association between HER2/neu and hormone receptor status in breast cancer: a review of the literature and implications for therapy." *Clinical Cancer Research*, 12(1), 1-8. <a href="Mouse Her2 / ErbB2 Protein ">https://pubmed.ncbi.nlm.nih.gov/?term=Mouse Her2 / ErbB2 Protein </a> <br><strong>Products Related to Mouse Her2 / ErbB2 Protein, His Tag can be found at</strong> <a href="https://moleculardepot.com/product-category/Enzymes/"> Enzymes</a>